Moderna Inc. ($MRNA) Stock Forecast: Down 5.1% Today

What is Moderna Inc.?

Moderna Inc. ($MRNA) is a biotechnology company recognized for its mRNA technology, including its COVID-19 vaccine, which has been pivotal in the battle against the pandemic. The stock faced a notable bearish movement recently.

Why is Moderna Inc. going down?

MRNA stock is down 5.1% on Mar 12, 2026 14:10

• The decline in Moderna's stock could be linked to profit-taking by institutional investors such as Jefferies Financial Group, which notably decreased its holdings in the company.
• Resolving patent disputes related to its COVID-19 vaccine possibly created uncertainty among investors, despite the settlement and licensing agreements in place.
• Reports of a federal vaccine advisory panel scrapping plans to scrutinize mRNA COVID shots might have raised worries about regulatory challenges or public reception of Moderna's mRNA technology.
• Analysts' consensus "Reduce" rating and apprehensions about inflated valuations likely added to the negative sentiment surrounding Moderna's stock movement.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

Roivant Sciences stock hits all-time high at 30.31 USD

Roivant Sciences (ROIV) stock has reached an all-time high of $30.31, leading to a market capitalization of $21.66 billion and a 185.38% increase over the past year. This surge is attributed to investor confidence in the company's biotech innovations, recent settlements, and promising clinical pipeline developments. Analysts have reacted positively, raising price targets and reiterating "Buy" and "Outperform" ratings, although InvestingPro data suggests the stock might be overvalued.

https://www.investing.com/news/company-news/roivant-sciences-stock-hits-alltime-high-at-3031-usd-93CH-4555012

Moderna Settles Patent Litigation with Arbutus et al.

Moderna has settled patent litigation with Arbutus Biopharma Corp. and Genevant Biosciences GmbH regarding its COVID-19 vaccine, agreeing to an immediate $950 million payment and a potential $1.3 billion more depending on its appeal concerning government responsibility under 28 U.S.C. § 1498(a). The settlement also includes a global nonexclusive license for Moderna's SM-102-containing mRNA vaccines for infectious diseases. This resolution comes amid a broader landscape of increased patent litigation related to COVID-19 vaccines, with similar lawsuits ongoing against other pharmaceutical companies.

https://www.jdsupra.com/legalnews/moderna-settles-patent-litigation-with-3250578/

Jefferies Financial Group Reduces Moderna Stake

Jefferies Financial Group has decreased its stake in Moderna Inc. by 25.3% during the third quarter, selling over 32,000 shares and now owning 95,266 shares valued at $2.46 million. This move by a major institutional investor could signal a shift in market sentiment towards Moderna and its COVID-19 vaccine, with implications for future revenue and growth prospects. Investors will be observing if other large funds follow suit in reducing their Moderna holdings.

https://nationaltoday.com/us/ma/cambridge/news/2026/03/11/jefferies-financial-group-reduces-moderna-stake/

Jefferies Financial Group Inc. Sells 32,310 Shares of Moderna, Inc. $MRNA

Jefferies Financial Group Inc. significantly reduced its stake in Moderna, Inc. by 25.3%, selling 32,310 shares and now holding 95,266 shares valued at $2.46 million. This reduction comes amid substantial insider selling from Moderna executives and a consensus "Reduce" rating from analysts with a target price of $32.33, despite the company beating revenue and EPS estimates in its latest quarterly report. Moderna's profitability remains negative with a net margin of -145.16%.

https://www.marketbeat.com/instant-alerts/filing-jefferies-financial-group-inc-sells-32310-shares-of-moderna-inc-mrna-2026-03-11/

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

A key U.S. federal vaccine advisory panel has reportedly dropped its plan to question COVID mRNA vaccines, according to the Washington Post. This comes after some advisers under Health and Human Services Secretary Robert F. Kennedy Jr. had sought to potentially halt recommendations for mRNA shots. The Department of Health and Human Services had previously decided to wind down mRNA vaccine development activities under Kennedy Jr.'s leadership, despite scientific evidence supporting their efficacy.

https://www.reuters.com/business/healthcare-pharmaceuticals/us-vaccine-advisers-drop-plan-question-mrna-covid-shots-wapo-reports-2026-03-11/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Up 5.4% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 6.3% Today

DaVita Inc. ($DVA) Stock Forecast: Down 5.2% Today

Advance Auto Parts Inc W/I ($AAP) Stock Forecast: Down 5.5% Today

MicroVision Inc. ($MVIS) Stock Forecast: Down 5.3% Today

Bruker Corporation ($BRKR) Stock Forecast: Down 6.1% Today

Global Payments Inc. ($GPN) Stock Forecast: Down 5.0% Today

Saia Inc. ($SAIA) Stock Forecast: Down 5.2% Today

Insulet Corporation ($PODD) Stock Forecast: Down 5.2% Today

Cassava Sciences, Inc. ($SAVA) Stock Forecast: Up 5.8% Today

Moderna Inc. Price History

02.02.2026 - MRNA Stock was up 5.6%

• Moderna's stock rose after receiving a favorable opinion from the European Medicines Agency's drug review committee for its dual Covid-flu vaccine. This places Moderna at the forefront of the global competition for a combined vaccine.
• Concerns expressed by Pfizer's CEO regarding FDA leadership and internal disagreements on vaccine strategies may have indirectly benefitted Moderna, highlighting potential regulatory advantages for the company.
• Analysts have a positive view on Moderna's stock, increasing price targets and emphasizing its robust vaccine pipeline, contributing to investor confidence and the stock's upward movement.
• Moderna's strategic shift towards cancer and rare disease pipelines, in addition to potential regulatory approvals across various regions, showcases the company's diversification beyond Covid-19 vaccines, making it an appealing option for investors.

10.02.2026 - MRNA Stock was up 5.8%

• Moderna's stock surged by 6.13% to an intraday high, showcasing robust investor confidence and market demand for the company's products.
• The company's narrower-than-expected Q4 loss and sales beating estimates indicate a positive financial performance, contributing to the bullish movement.
• Strong short-term gains, including an 89.01% year-to-date increase, coupled with high institutional holdings at 80.65%, further bolster investor sentiment in Moderna.
• Eric Green's retirement at West Pharmaceutical, a key player in vaccine distribution, may have indirectly contributed to positive market sentiment towards Moderna, emphasizing the critical role of vaccine-related companies in the current economic landscape.

04.02.2026 - MRNA Stock was up 7.6%

• Following the announcement of a $950 million settlement to resolve patent infringement claims with Arbutus Biopharma Corp and Genevant Sciences GmbH, Moderna's stock saw a notable bullish trend.
• This settlement eliminated a significant financial risk for Moderna, increasing investor confidence in the company's future.
• Despite the substantial settlement, investors interpreted this news positively for Moderna, resulting in the bullish market movement.
• The information about the settlement overshadowed insider sales at Axsome Therapeutics and routine equity compensation activities at Molson Coors Beverage Co, underscoring the impact of legal resolutions on market sentiment.

04.02.2026 - MRNA Stock was up 13.4%

• Moderna's stock saw a notable rise following the resolution of patent disputes with Arbutus and Roivant, resulting in a settlement of up to $2.25 billion. This development brought clarity to Moderna's mRNA pipeline and eliminated a substantial financial risk.
• The settlement news generated optimism among investors regarding Moderna's forthcoming product innovations and potential revenue sources.
• Investor sentiment was positively influenced by the resolution of the legal issues, underscoring the importance of Moderna's capacity for innovation and product launches in sustaining long-term growth and success.

05.02.2026 - MRNA Stock was down 5.5%

• Moderna experienced a bearish movement possibly due to the settlement it reached with Roivant Sciences and Arbutus Biopharma, which involved significant payouts, impacting its financials negatively.
• The positive news of being a top leader among stocks on Wednesday might have been overshadowed by the impact of the settlements on Moderna's finances.
• The increase in headcount by some Massachusetts biotech companies, including Moderna, in 2025, could indicate potential operational expansions that might have been affected by the recent legal settlements.

05.02.2026 - MRNA Stock was up 7.7%

• Moderna's recent positive developments include a substantial $2.25 billion settlement with Roivant Sciences, resolving patent disputes on lipid nanoparticle technology in COVID-19 vaccines. This settlement not only removes a legal overhang but also shows the company's ability to protect its intellectual property rights effectively.
• Another significant development is Moderna's $950 million settlement with Arbutus Biopharma, providing clarity and resolution on a patent infringement lawsuit related to its Covid-19 vaccine, Spikevax.
• The company's decision to add workers in 2025 amidst industry-wide layoffs suggests strategic growth plans and commitment to expanding its workforce to support research and development efforts, potentially boosting investor confidence in the stock.
• These settlements, coupled with workforce expansion and positive industry developments, may have contributed to investor optimism in Moderna, driving its strong bullish movement in the market.

06.02.2026 - MRNA Stock was down 10.0%

• Moderna's bearish movement today could be attributed to profit-taking by investors after a period of strong gains or concerns about the company's future growth prospects.
• The news about PepGen's muscular dystrophy drug facing FDA hold may have negatively impacted Moderna, as it highlights the regulatory challenges and uncertainties in the biotech industry.
• Additionally, the wider loss and revenue miss by D-Wave Quantum could have spooked investors in the biotech sector, leading to a broader sell-off that affected Moderna's stock price.
• Overall, the combination of regulatory hurdles, financial performance of related companies, and profit-taking behavior likely contributed to Moderna's bearish movement today.

09.02.2026 - MRNA Stock was down 5.4%

• Sienna Gestion and Quantbot Technologies LP both made significant reductions in their stakes in Moderna, Inc., indicating a lack of confidence in the company's future performance.
• Concerns about Moderna's cash burn post a costly patent settlement and insider selling have led to a cautious outlook among analysts, resulting in a "Reduce" rating and a reduced average price target.
• While the bullish options flow and the resolution of legal issues have generated some positive sentiment, uncertainty regarding regulations and the financial repercussions of the settlement are dampening the stock's performance.
• In summary, today's downward trend in Moderna's stock can be attributed to a mix of decreased investor confidence, financial issues, and regulatory uncertainties stemming from the recent patent settlement.

03.02.2026 - MRNA Stock was down 6.2%

• The decline in Moderna's stock today is possibly due to investors taking profits following a period of successful performance.
• Merck's notable revenue growth fueled by Keytruda, a competitor PD-1 inhibitor, might have sparked concerns about potential competition for Moderna in the immuno-oncology sector.
• The proposed stock offering by MAIA Biotechnology to finance trials could have affected Moderna's stock price, as investors may be wary of potential dilution in the biotech industry.
• Despite optimistic outlooks from analysts and advancements in its pipeline, general market sentiment regarding regulatory approvals and market acceptance of Moderna's mRNA-based vaccines may be influencing the stock's movements.

03.02.2026 - MRNA Stock was down 6.3%

• Analysts are bullish on Moderna, maintaining Buy ratings and positive price targets, indicating long-term growth potential.
• The transition to a more diversified business model, including RSV and flu vaccines, has garnered investor interest, but concerns remain regarding regulatory approvals and market adoption.
• The decline in Moderna's stock price could be attributed to the negative market reaction to MAIA Biotechnology's stock sale announcement, raising concerns about potential dilution for existing shareholders.
• Despite positive news of Moderna's dual Covid-flu vaccine nearing EMA approval, regulatory hurdles in the US for other vaccines and shifting focus to different pipelines may have contributed to the bearish market movement.

11.02.2026 - MRNA Stock was up 5.6%

• Reduction of stake in Moderna by 25.3% by Jefferies Financial Group initially sparked concerns regarding the company's future outlook. However, the strong bullish movement today indicates ongoing investor optimism towards Moderna's growth potential.
• Uptick in Moderna's stock following US vaccine advisors' decision not to question mRNA COVID shots could have boosted investor confidence in the company. This move reaffirms faith in mRNA technology, crucial for Moderna's vaccine innovation.
• Moderna's stock surged 6.13% to hit a day high, outperforming the S&P 500. This indicates a positive market response to the company's recent performance and its potential for future growth, despite past long-term declines.
• Favorable sentiment in the therapeutics sector, marked by companies surpassing revenue expectations, may have also contributed to the bullish movement in Moderna's stock. Investors are demonstrating increased interest in the healthcare industry overall.

12.02.2026 - MRNA Stock was down 5.1%

• The decline in Moderna's stock could be linked to profit-taking by institutional investors such as Jefferies Financial Group, which notably decreased its holdings in the company.
• Resolving patent disputes related to its COVID-19 vaccine possibly created uncertainty among investors, despite the settlement and licensing agreements in place.
• Reports of a federal vaccine advisory panel scrapping plans to scrutinize mRNA COVID shots might have raised worries about regulatory challenges or public reception of Moderna's mRNA technology.
• Analysts' consensus "Reduce" rating and apprehensions about inflated valuations likely added to the negative sentiment surrounding Moderna's stock movement.